A Phase I/II study of JR-031 for the patients of standard primary treatment-refractory acute graft-versus-host disease (acute GVHD) after hematopoietic stem cell transplantatio
Phase 1
- Conditions
- Standard primary treatment-refractory acute GVHD
- Registration Number
- JPRN-UMIN000001716
- Lead Sponsor
- JCR pharmaceuticals Co.,Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
*Patients who had the acute GVHD therapy except standard therapy with corticosteroids. *Patients who had the hematopoietic transplantation while their malignant disease was not remitted (except for the patients who have little possibility of early relapse). *Oxygen gas saturation in rest < 94%.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effectiveness of GVHD treatment from the first dose point to 4 weeks later and others
- Secondary Outcome Measures
Name Time Method